AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 5 - (NewsRx.com & NewsRx.net) -- Physicians and patients alike are reluctant to use tamoxifen, an adjuvant therapy in the treatment of the very earliest form of breast cancer - ductal carcinoma in situ (DCIS) - because of its side effects, potential complications, and marginal efficacy, according to study findings.
Tamoxifen is an estrogen hormone-regulating drug used to prevent recurrence of breast cancer after surgery. It has been shown to decrease mortality in women with invasive breast cancer. However, in the landmark 1999 study called the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24, tamoxifen was tested in women with DCIS following breast-conserving surgery. In contrast to invasive breast cancers, the absolute risk reduction for cancer recurrence was marginal at only 5% in patients with DCIS, and there was no reduction in mortality.
Studies have also shown that tamoxifen increases the risk of endometrial cancer and thromboembolic events, such as pulmonary emboli, particularly in postmenopausal women. Other potential side effects include hot flashes, vaginal bleeding, and cataract formation.
To evaluate the impact of the NSABP B-24 trial on current clinical ...